tiprankstipranks
Trending News
More News >
Centogene (CNTGF)
OTHER OTC:CNTGF

Centogene (CNTGF) AI Stock Analysis

Compare
122 Followers

Top Page

CN

Centogene

(OTC:CNTGF)

Rating:34Underperform
Price Target:
Centogene's stock is struggling primarily due to poor financial performance, characterized by persistent losses, negative cash flow, and high leverage. Technical analysis points to a bearish trend, and valuation metrics are unattractive with a negative P/E ratio and no dividend yield. The significant drop in stock price post-earnings call further highlights market concerns, resulting in a low overall stock score.

Centogene (CNTGF) vs. SPDR S&P 500 ETF (SPY)

Centogene Business Overview & Revenue Model

Company DescriptionCentogene (CNTGF) is a global leader in the field of rare disease diagnostics and genetic testing. The company operates within the biotechnology and life sciences sectors, providing comprehensive diagnostic solutions to healthcare providers, pharmaceutical companies, and research institutions. Centogene's core services include genetic testing, biomarker discovery, and data-driven insights, all aimed at improving patient outcomes and advancing precision medicine.
How the Company Makes MoneyCentogene generates revenue primarily through its diagnostic services and collaborations with pharmaceutical companies. The company offers a wide range of genetic testing services, including whole exome and genome sequencing, which are utilized by healthcare providers to diagnose rare hereditary diseases. Additionally, Centogene partners with pharmaceutical companies to support drug development and clinical trials by providing biomarker discovery and patient stratification services. These partnerships often involve long-term contracts and collaborative research agreements, contributing significantly to the company's earnings. Centogene's extensive database of genetic information also provides a valuable resource for research and development, enabling further monetization opportunities through licensing and data-driven projects.

Centogene Financial Statement Overview

Summary
Centogene faces significant financial challenges with persistent losses, negative cash flow, and high leverage. The company demonstrates poor profitability and cash flow performance, alongside a deteriorating balance sheet.
Income Statement
35
Negative
Centogene's revenue growth is stagnant with only a marginal increase in the last year, and the company is struggling with profitability as it reports negative net income consistently. Gross profit margin has decreased significantly compared to earlier years. Both EBIT and EBITDA margins are negative, indicating operational inefficiencies.
Balance Sheet
20
Very Negative
The company exhibits a high debt-to-equity ratio due to negative equity, indicating potential financial instability. Stockholders' equity has deteriorated significantly, and liabilities exceed assets, raising concerns about solvency. Return on equity is negative, reflecting the company's inability to generate profits from its equity base.
Cash Flow
30
Negative
Operating cash flow has turned negative, and free cash flow is also negative, indicating cash burn. The company has been relying on external financing to cover cash shortfalls. The free cash flow to net income ratio is negative, reflecting poor cash conversion efficiency.
BreakdownDec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Income Statement
Total Revenue
Gross Profit17.25M19.76M28.16M44.94M22.77M
EBITDA-20.48M-55.30M-24.73M-4.93M-12.09M
Net Income-35.53M-63.83M-92.62M-21.38M-20.86M
Balance Sheet
Total Assets77.16M92.81M90.69M150.13M117.51M
Cash, Cash Equivalents and Short-Term Investments
Total Debt80.73M60.12M22.81M24.10M26.97M
Total Liabilities102.44M88.71M65.90M84.35M58.59M
Stockholders Equity
Cash Flow
Free Cash Flow-33.94M4.00M-27.23M-8.09M-15.35M
Operating Cash Flow-31.75M5.23M-21.70M8.46M-7.78M
Investing Cash Flow
Financing Cash Flow

Centogene Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.15
Price Trends
50DMA
0.15
Positive
100DMA
0.15
Positive
200DMA
0.15
Positive
Market Momentum
MACD
<0.01
Positive
RSI
50.21
Neutral
STOCH
22.99
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CNTGF, the sentiment is Positive. The current price of 0.15 is below the 20-day moving average (MA) of 0.15, above the 50-day MA of 0.15, and above the 200-day MA of 0.15, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 50.21 is Neutral, neither overbought nor oversold. The STOCH value of 22.99 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CNTGF.

Centogene Risk Analysis

Centogene disclosed 88 risk factors in its most recent earnings report. Centogene reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Centogene Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
73
Outperform
$22.06B-18.66%51.50%53.23%
72
Outperform
$10.53B116.532.67%2.71%3.31%-72.63%
GHGH
57
Neutral
$6.28B-4584.47%28.20%13.87%
53
Neutral
$1.79B19.61-23.61%59.15%-1881.09%
52
Neutral
$611.92M-3.61%1.71%76.00%
51
Neutral
$7.50B0.32-61.87%2.27%17.10%1.59%
45
Neutral
$518.96M-13.84%7.38%60.45%
34
Underperform
$4.44M140.54%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
CNTGF
Centogene
0.15
-0.29
-65.91%
MYGN
Myriad Genetics
5.63
-19.27
-77.39%
QGEN
Qiagen
48.64
7.76
18.98%
SRPT
Sarepta Therapeutics
18.20
-133.53
-88.01%
NTRA
Natera
161.57
48.83
43.31%
FLGT
Fulgent Genetics
20.10
0.48
2.45%
GH
Guardant Health
50.18
21.43
74.54%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Dec 14, 2024